Tarlatamab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Tarlatamab. Educational only — not medical advice.
Labeled uses
IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
Source: FDA labeling via NIH DailyMed (set 1e7b6163…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.